supplier
Lipomed AG
as a supplier
3 recorded awards from 2 buyers , between 13 Jan 2026 and 24 Mar 2026.
“Exclusive” means this organisation was the only one awarded under that procurement; the rest were shared with other suppliers, typically on a framework.
No median is shown because every award here carries a framework ceiling rather than a settled price. A ceiling is the most that could be spent across every supplier on the agreement, so averaging them would overstate this organisation’s work, often by an order of magnitude. The individual values are listed below as published.
sells to
| buyer | awards |
|---|---|
| NHS England | 2 |
| NHS England | 1 |
contracts won
| contract | buyer | value | awarded |
|---|---|---|---|
| NHS Generic Pharmaceuticals - Lenalidomide, Pomalidomide & Thalidomide shared | NHS England | £19,595,208 | 24 Mar 2026 |
| NHS National Generic Pharmaceuticals - Wave 15c shared | NHS England | £403,702,000 | 13 Jan 2026 |
| NHS National Generic Pharmaceuticals Wave 15b shared | NHS England | · | 4 Aug 2025 |
every contract won by Lipomed AG →
as published
This page combines 2 separate records from the source data. Every one is listed below exactly as the publisher filed it, so you can check the grouping yourself.
| name as published | identifier | postcode | records |
|---|---|---|---|
| Lipomed AG | GB-PPON PLZZ-7452-XPLQ | 79576 | 2 |
| Lipomed AG | · | · | 1 |
why these were combined
- identical name · lipomed ag 1
Matching uses organisation identifiers where publishers provide them, falling back to name and address. Records are never combined on address alone, because one shared-service postcode carries 244 different organisations. how this works